Table 3.
Selected prospective clinical trials in MM, adapted from [42].
| Trial Collaborative/Institution | Trial | Phase | Trial designation | Patient cohort | Study details |
|---|---|---|---|---|---|
| University of Freiburg | VBDD [83] | I/II | NCT01394354 | 33 | QoL & frailty improvements in disease responsiveness |
| City of Hope/ University of Rochester | Touch-screen based GA | IV | NCT03068637 | 165 | Utility of technology to improve clinic applicability of GA usage |
| GIMEMA | Rd vs Rd-R in unfit MM [84] | II | NCT02215980 | 210 | Rd-R improved outcomes for unfit patients |
| HOVON | HOVON 143: Efficacy & tolerability of IDd in unfit & frail patients | II | NCR6297 | 130 | Dose-adjustments feasible though effect on early mortality still to be defined |
| UKMRA | UKMRA Myeloma XIV (FiTNEss) trial: Use of frailty scores to direct clinical treatment adjustments (IRD) in TNE NDMM. | III | NCT03720041 | 740 | Frailty-adapted versus toxicity-responsive dose adjustments and impact on outcomes including early mortality |
QoL quality of life, GA geriatric assessment, Rd lenalidomide and dexamethasone, IDd ixazomib, daratumumab & dexamethasone, IRD ixazomib, lenalidomide & dexamethasone, TNE- transplant ineligible, NDMM new diagnosed MM.